Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib +/- Trametinib Pre-op in Melanoma Brain Mets
NCT01978236Phase 2Terminated
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by GSK. Started Apr 2014; status: terminated.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01978236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01978236.